very soon. If the mkt was not doing so good today, we would see something south of $2.80. I feel when the news sinks in, we will go below $2.80 and i will get back in. Good Luck!
<a href="http://www.thestreet.com/_yahoo/story/10477719/1/neurocrines-elagolix-misses-main-study-goal.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA" rel="nofollow">http://www.thestreet.com/_yahoo/story/10477719/1/neurocrines-elagolix-misses-main-study-goal.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA</a>
No drug will ever be approved with exploratory endpoints alone. The endpoints were clear and were NOT exploratory at beginning of trial. Primary endpoint failure: game over. You just answered your own question. Nice investment strategy you have, buy companies that fail to reach primary endpoints in controlled trials? LMAO!
The endpoints were exploratory so whats teh big deal? On the validated scales, teh study came out very good as it did previously.
No adverse effects of any significance either.
This drug will be approved. Royalty payments will be more than $2 a share when they start selling. I think this company will be bought out much before that.
Endpoints were clearly defined and NBIX missed them. Go back and read the study. I will be more specific: Show me an exploratory endpoint on a p2 trial anywhere. Doesn't exist, just a pathetic way to spin the failed endpoint.
this was not a P3 trial, you run a seies of P2's to develop P3 trial design. The end points for those trials have not been defined.
How do you measure pelvic pain on a daily basis when it only occurs during the menstral cycle.........not very well. The approach applied to measure pain via these newly designed endpoints was flawed.